

PRESS RELEASE

Beactica expands into new premises

Uppsala, Sweden, 1 November 2007

Beactica, the specialist drug discovery company spun out of Uppsala University in 2006, announced today that it has moved into new premises at the Uppsala Biomedical Centre.

“The move reflects a growing demand for Beactica’s partnership programme from other drug discovery companies.” said Dr Per Källblad, Beactica CEO. “It also prepares us for an increase in the number of Beactica full time employees in conjunction with the start of our two EU-funded drug discovery projects”.

The Uppsala Biomedical Centre provides a world-class environment for both scientists and entrepreneurs in the life sciences. It harbours activities in the areas of biology, chemistry, medicine and pharmacy.

“The move to our new premises indicates a gear shift for Beactica and will enable us to increase the discovery throughput without compromising the quality of our research” said Beactica’s CSO, Professor Helena Danielson.



For additional information please contact Dr Per Källblad, Beactica CEO, +46 730 67 44 88.

About Beactica

Beactica AB is a specialist drug discovery company, utilising its proprietary methodologies to evaluate the biophysical interaction of molecules in order to generate novel therapeutics.

For more information about Beactica, please visit www.beactica.com.

New postal address

Box 567
SE-751 22 Uppsala
Sweden

New visiting address

Husargatan 3, BMC
SE-752 37 Uppsala
Sweden